|
Rohto Pharmaceutical Co., Ltd. is a health and beauty care company that manufactures and sells products across five main segments: eye care, skin care, internal medicine and food, medical, and other. Its eye care portfolio includes eye drops and eye washes, while skin care products comprise topical medicines, lip creams, sunscreens, and functional cosmetics. The internal medicine and food segment covers gastrointestinal drugs, traditional Chinese medicine, and supplements. The medical segment includes contract development and manufacturing organizations (CDMO) services and ophthalmic pharmaceuticals, alongside other products such as in-vitro diagnostic kits. The company operates globally through regional subsidiaries, including Mentholatum in the Americas, Europe, and Asia-Pacific, and Yu Yung Shing International in Asia for internal medicine and food products. Key subsidiaries in Japan include Rohto Nitten and Qualtech Pharma, which focus on medical products, and Rohto USA and Rohto Brasil in the Americas. In Europe, Mentholatum UK handles business operations, while in Asia, entities such as Rohto Mentholatum Vietnam, Rohto Indonesia, and Tianjin Rohto support regional manufacturing and sales. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage rohto.co.jp |
| Sector Healthcare | IR page rohto.co.jp | |
|
Tags
eye care, skin care, topical medicines, functional cosmetics, gastrointestinal drugs, traditional chinese medicine, supplements, cdmo, ophthalmic pharmaceuticals, in-vitro diagnostics, Mentholatum, Yu Yung Shing International, Rohto Nitten, Qualtech Pharma, Rohto USA, Rohto Brasil, Mentholatum UK, Rohto Mentholatum Vietnam, Rohto Indonesia, Tianjin Rohto, Mentholatum Asia Pacific, Mentholatum China, Rohto Pharma India, Rohto Mentholatum Bangladesh, Mentholatum Australia, Anz Corporation, Aman Pharmaceutical, Biomimetics Symposia, Offalmos, Rohto Brasil Holdings, Rohto Medilux Europe, Mentholatum Mexico, Mentholatum Taiwan, Soar R2M, Hong Kong Lab
|
Press page rohto.co.jp/ir/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 657.166B |
| Market cap (USD) | $ 4.107B |
| P/E | 18.99 |
| PEG | 2.09 |
| P/BV | 1.96 |
| P/S | 1.83 |
| P/OCF | 13.15 |
| P/FCF | 29.85 |
| Dividend yield | 1.7% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 11.6% |
| ROI | 9.8% |
| ROIC | 8.7% |
| Profit margin | 10.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 9.1% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 35 |
| Quality score | 27.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 343.725B | 308.625B | 270.84B | 238.664B | 199.646B | 181.287B | 188.327B | 183.582B | 171.742B | 154.599B | 167.016B | 151.774B | 143.822B | 129.146B |
| Net profit | 34.247B | 31.006B | 30.936B | 26.377B | 21.018B | 16.743B | 15.41B | 9.799B | 9.289B | 10.011B | 9.098B | 8.631B | 8.947B | 8.087B |
| Free cash flow | 21.537B | 27.837B | 25.333B | 21.016B | 15.922B | 9.704B | 12.607B | 15.329B | 13.702B | 9.448B | 6.593B | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 2.411K | 2.234K | 2.969K | 2.771K | 3.697K | 2.953K | 2.96K | 2.841K | 2.976K | 2.085K | 2.049K | 1.709K | 1.821K | 1.287K |
| Price performance 12m | 0.08 | -0.25 | 0.07 | -0.25 | 0.25 | -0 | 0.04 | -0.05 | 0.43 | 0.02 | 0.2 | -0.06 | 0.42 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 46.6B | 50.3B | 44.8B | 50.8B | 48.2B | 85.2B | 101B | 114B | 118B | 130B |
| ↳ YoY growth | -4.9% | +8.1% | -11.1% | +13.5% | -5.2% | +76.9% | +18.2% | +13.5% | +2.8% | +10.6% |
| ↳ 5y CAGR | -0.3% | +12.8% | +14.9% | +20.6% | +18.3% | +22.0% | ||||
| Borrowings, current (JPY) | 3.35B | 4.15B | 3.75B | 2.11B | 2.31B | 8.03B | 4.18B | 5.3B | 7.04B | 24.7B |
| Borrowings, non-current (JPY) | 1.77B | 1.7B | 1.42B | 5.19B | 5.79B | 13.4B | 7.52B | 5.19B | 43.2B | 28.2B |
| Bonds payable (JPY) | — | — | — | — | — | — | — | — | 25.4B | 25.3B |
| Lease liabilities (JPY) | — | — | — | — | — | — | — | — | 7.19B | 7.31B |
| Cash and deposits (JPY) | 23.9B | 30.5B | 37.9B | 45.3B | 53B | 72.8B | 80B | 89.2B | 77.2B | 86.8B |
| Intangible assets (JPY) | 2.66B | 4.11B | 3.57B | 5.32B | 7.54B | 9.29B | 9.56B | 9.22B | 56.1B | 83.9B |
| Net debt (borrowings + leases - cash) (JPY) | -18.8B | -24.7B | -32.7B | -38B | -44.9B | -51.4B | -68.3B | -78.7B | -26.9B | -26.6B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 13.4B | 19.2B | 21.7B | 19B | 20B | 27.3B | 30.9B | 34.2B | 36.9B | 47.8B |
| Purchases of property, plant and equipment (JPY) | -3.78B | -5B | -6.42B | -5.59B | -8.72B | -10.3B | -8.47B | -7.98B | -9.08B | -11.5B |
| Purchases of intangible assets (JPY) | -203M | -452M | -501M | -847M | -1.58B | -1.06B | -1.44B | -933M | -1.48B | -14.8B |
| Change in receivables (cash effect) (JPY) | 1.27B | -2.82B | 5.34B | -4.3B | 2.46B | -30M | -7.56B | -6.79B | 1.95B | -5.18B |
| Change in inventories (cash effect) (JPY) | -827M | -2.19B | -4.36B | 892M | 3.19B | -3.06B | -6.11B | -4.03B | -4.6B | -2.07B |
| Change in payables (cash effect) (JPY) | 165M | 3.09B | -984M | -900M | -2.81B | 3.32B | 1.72B | 1.68B | -1.29B | -141M |
| Dividends paid (cash effect) (JPY) | -2.28B | -2.51B | -2.51B | -3.08B | -2.97B | -3.42B | -4.68B | -5.48B | -7.07B | -9.26B |
| Share buybacks (cash effect) (JPY) | — | — | — | — | — | — | — | 0.00 | -5B | 0.00 |
| Interest paid (cash effect) (JPY) | -141M | -147M | -150M | -130M | -143M | -228M | -247M | -200M | -888M | -1.31B |
| Income taxes paid (cash effect) (JPY) | -6.14B | -5.17B | -5.98B | -6.64B | -7.8B | -8.82B | -6.96B | -10B | -11.2B | -11.9B |
| Operating cash flow before change in receivables (JPY) | 12.2B | 22B | 16.4B | 23.3B | 17.5B | 27.3B | 38.5B | 41B | 35B | 53B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 9.45B | 13.7B | 14.8B | 12.6B | 9.7B | 15.9B | 21B | 25.3B | 26.4B | 21.5B |
| Income detail | ||||||||||
| Research and development expense (JPY) | 6.15B | 6.58B | 6.91B | 7.08B | 7.94B | 8.78B | 11.1B | 13.5B | 15B | 13.9B |
| ↳ 5y CAGR | +6.4% | +7.4% | +11.1% | +14.3% | +16.2% | +11.8% | ||||
| Total comprehensive income (JPY) | 9.31B | 12.2B | 6.14B | 11.3B | 19.8B | 26.8B | 36.5B | 43.6B | 35B | 48.8B |
| Comprehensive income to owners (JPY) | 9.33B | 12.1B | 6.26B | 11.4B | 19.8B | 26.6B | 36.3B | 43.1B | 35.2B | 47.8B |
| Provision for credit losses (JPY) | 996M | 209M | 331M | 202M | 1.21B | 1.03B | 620M | 47M | 483M | 390M |
| Credit cost ratio (credit losses / average receivables) (%) | 2.1% | 0.4% | 0.7% | 0.4% | 2.5% | 1.5% | 0.7% | 0.0% | 0.4% | 0.3% |
| Reported | Jun 26, 2017 | Jun 25, 2018 | Jun 28, 2019 | Jun 29, 2020 | Jun 25, 2021 | Jun 28, 2022 | Jun 29, 2023 | Jun 25, 2025 | Jun 19, 2026 | Jun 19, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Rohto Pharmaceutical Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVDS | 0.12% | 27,700 | $ 446.27K | Nov 16, 2026 |
| DFIS | 0.04% | 143,752 | $ 2.415M | Nov 12, 2026 |
| DXIV | 0.03% | 5,000 | $ 84.006K | Nov 12, 2026 |
| DFIC | 0.02% | 217,300 | $ 3.651M | Nov 12, 2026 |
| DFAX | 0.02% | 141,800 | $ 2.382M | Nov 12, 2026 |
| DFAI | 0.01% | 157,748 | $ 2.65M | Nov 12, 2026 |
| AVDE | 0.01% | 100,700 | $ 1.622M | Nov 16, 2026 |











































